TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Average Target Price from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $12.08.

A number of equities analysts have issued reports on the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Roth Mkm started coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 price target on the stock. Northland Securities began coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Finally, Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th.

Insider Activity

In other news, CEO Mary T. Szela acquired 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the acquisition, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This represents a 2.03 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have purchased a total of 14,560 shares of company stock worth $72,440 in the last ninety days. Corporate insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the third quarter worth $66,000. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences during the third quarter worth approximately $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the third quarter worth approximately $184,000. Finally, Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $240,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $4.53 on Wednesday. The stock’s fifty day moving average is $4.25 and its two-hundred day moving average is $5.56. The stock has a market capitalization of $138.12 million, a price-to-earnings ratio of -1.82 and a beta of 0.49. TriSalus Life Sciences has a 1 year low of $3.33 and a 1 year high of $10.42.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.